China’s generic drug industry undergoes an overhaul
China’s $90 billion generic drug market is at the verge of a revolution, with the launch of national regulatory reforms that aim to centralize drug procurement and assure quality control in this highly fragmented and unregulated market. How will these reforms—the generic quality consistency evaluation (GQCE) process and the volume-based procurement (VBP) programs—assure patient-access to high-quality and cost-effective generic medicines in China?
In this webinar, we will discuss how China’s pharmaceutical market is responding to the early wave of these regulatory reforms and how the market is expected to emerge in the future with these reforms fully established.
Evolving biosimilars landscape
In recent years, the availability of biosimilars has significantly disrupted the biopharmaceutical industry, and there are many more on the way with over 400 biosimilars in clinical development globally. As regions around the world continue to pave regulatory frameworks for biosimilar development, alongside expiring patents for key biologic drugs, this evolving landscape presents a commercial opportunity to biosimilar manufacturers that is undeniably large.
In this webinar, we look at the biosimilar landscape across the major markets—where biosimilars have become well-established—providing an overview of regulatory guidelines, clinical development activity, and drivers and barriers to biosimilar adoption
Focus on Indian generics and API industry
The current pandemic has brought the growth of Indian pharmaceutical market to a halt and majority of Indian pharmaceutical companies are forced to realign their strategies for growth to circumvent the challenges posed by current situation.
In this webinar, we will provide a brief overview of the Indian pharmaceutical industry, discuss the challenges and opportunities arising from the current pandemic, and answer two key questions to help you drive growth and stay ahead of competition:
• How can you optimize API supply and product portfolio in changing dynamics?
• How can you emerge as leaders in generics manufacturing?